IRB Barcelona and the BBVA Foundation invite twenty international experts in therapeutic peptide engineering to a Barcelona BioMed Conference, which will be held in Barcelona from 26 to 28 October.
Researchers at IRB Barcelona participate in the scientific workshop series “FES RECERCA” (Do research), which is addressed to secondary school students and teachers, and the public at large.
Tuberculosis is one of the major health threats worldwide. Every year more than 2 million people die from this infectious disease, which is caused by Mycobacterium tuberculosis. The lack of effectiveness of drug treatments because of the appearance of strains that show multi-resistance to new drugs has made tuberculosis a focus of international research to define new therapeutic tools against this disease.
The study provides further insight into how cells divide to form the wing during the embryonic development of the fly Drosophila.
Researchers at IRB Barcelona publish a review article in Physiological Reviews about the changes in the shape and movements of mitochondria, and the human diseases associated with defects in these processes. This review establishes a new interface between cell biology and pathology.
IRB Barcelona and the BBVA Foundation bring together a select group of international researchers who use the fruit fly Drosophila melanogaster to study cancer.
An IRB Barcelona research team discovers the mechanism that favours the correct separation of germ cells –future ovules and sperm-, from the rest of the cells during embryonic development.
“Bisthiazol” is funded by the Agency for Assessing and Marketing Research Results, run by the University of Barcelona (UB), and the Santander Bank.
At the end of 2011, IRB Barcelona will host 40 PhD students supported by this organisation.
The compound stimulates the growth of damaged axons in mouse neurons in vitro.